Cargando…

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression

BACKGROUND: Cancer targeting nanoprobes with precisely designed physicochemical properties may show enhanced pharmacological targeting and therapeutic efficacy. As a widely used commercialized antibody, rituximab has been in clinical use for three decades and has lengthened or even saved thousands o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Lina, Zhang, Wei, Chen, Hong, Zhang, Xizhi, Wu, Haoan, Ma, Ming, Wang, Zhongqiu, Gu, Ning, Zhang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363495/ https://www.ncbi.nlm.nih.gov/pubmed/30787607 http://dx.doi.org/10.2147/IJN.S185458

Ejemplares similares

Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine
por: Jo, Tatsuro, et al.
Publicado: (2012)

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
por: Mishima, Y, et al.
Publicado: (2011)

Systemic anti-CD20 (rituximab) as primary treatment for symptomatic primary uveal lymphoma
por: Tiu Teo, Honeylen Maryl, et al.
Publicado: (2019)

Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells
por: Luo, Chengke, et al.
Publicado: (2016)

Development of an aptamer-conjugated fluorescent nanoprobe for MMP2
por: Han, Myoung-Eun, et al.
Publicado: (2014)

Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma
por: Zhou, Shoubing, et al.
Publicado: (2016)

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
por: Chu, Te-Wei, et al.
Publicado: (2015)

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster
por: Li, Huafei, et al.
Publicado: (2015)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
por: Tsutsumi, Yutaka, et al.
Publicado: (2016)

Formation of miRNA Nanoprobes—Conjugation Approaches Leading to the Functionalization
por: Vilímová, Iveta, et al.
Publicado: (2022)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2021)

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases
por: Peterlin, Pierre, et al.
Publicado: (2018)

Capability of novel fluorescence DNA-conjugated CdTe/ZnS quantum dots nanoprobe for COVID-19 sensing
por: Bardajee, Ghasem Rezanejade, et al.
Publicado: (2022)

CD20(+) cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: Case report and review of the literature
por: Tschetter, Amanda J., et al.
Publicado: (2020)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Retraction note: Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma
por: Zhou, Shoubing, et al.
Publicado: (2017)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Luo, Chengxin, et al.
Publicado: (2021)

Cd20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab
por: Rasheed, Afshan Asghar, et al.
Publicado: (2018)

Conjugates of Ultrasmall Quantum Dots and Acridine Derivatives as Prospective Nanoprobes for Intracellular Investigations
por: Linkov, Pavel, et al.
Publicado: (2021)

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
por: Hicks, Stuart W., et al.
Publicado: (2017)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2013)

Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study
por: Jiang, Bo, et al.
Publicado: (2020)

Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin
por: Fang, Jun, et al.
Publicado: (2015)

Fabrication and Verification of Conjugated AuNP-Antibody Nanoprobe for Sensitivity Improvement in Electrochemical Biosensors
por: Khashayar, Patricia, et al.
Publicado: (2017)

Bioengineered Fluorescent Nanoprobe Conjugates for Tracking Human Bone Cells: In Vitro Biocompatibility Analysis
por: Salgado, Christiane L., et al.
Publicado: (2021)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells
por: Zhou, Shoubing, et al.
Publicado: (2017)

Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20
por: Winiarska, Magdalena, et al.
Publicado: (2008)

Tumor-targeted bioactive nanoprobes visualizing of hydrogen peroxide for forecasting chemotherapy-exacerbated malignant prognosis
por: Zhang, Fan, et al.
Publicado: (2023)

One nanoprobe, two pathogens: gold nanoprobes multiplexing for point-of-care
por: Veigas, Bruno, et al.
Publicado: (2015)

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
por: Salles, Gilles, et al.
Publicado: (2017)

Ratiometric Fluorescent Nanoprobe for Highly Sensitive Determination of Mercury Ions
por: Luo, Zhihui, et al.
Publicado: (2019)

Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis
por: Zhao, Xia, et al.
Publicado: (2018)

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study
por: Petrini, Mario, et al.
Publicado: (2022)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cethvgk39dm6tc2m25i4hom5q1